In January 2012, vismodegib was approved by the FDA for the treatment of unresectable or metastatic basalcellcarcinomasoftheskin.
2
Patients develop multiple basalcellcarcinomasoftheskin frequently in early life and also have a predisposition to additional malignancies such as medulloblastoma.